Fred Ramsdell
Fred Ramsdell | |
|---|---|
| Born | Frederick J. Ramsdell 1960 (age 65–66) |
| Awards | Crafoord Prize (2017) Nobel Prize in Physiology or Medicine (2025) |
| Scientific career | |
| Institutions | Parker Institute for Cancer Immunotherapy |
Frederick J. "Fred" Ramsdell (born 1960) is an American immunologist. He is the Research Director at the Parker Institute for Cancer Immunotherapy in San Francisco. In 2025, he was awarded the Nobel Prize in Physiology or Medicine for his work in peripheral tolerance.[1] In 2017, he was awarded the Crafoord Prize.
References
- ↑ "Nobel Prize in Physiology or Medicine 2025". NobelPrize.org. Retrieved 6 October 2025.
Other websites
- "The Founders". Sonoma Biotherapeutics. 9 February 2023. Retrieved 6 October 2025.
- Fred Ramsdell bio Parker Institute for Cancer Immunotherapy
- Ramsdell, Fred (May 23, 2017). "History of FoxP3 and implications for therapeutic intervention in disease, Crafoord Prize Lectures in Polyarthritis, 2017-5-16". YouTube.
This short article about a person or group of people can be made longer. You can help Wikipedia by adding to it.Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.